Cargando…

Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study

BACKGROUND: The various subcategories under the overarching term of steatotic liver disease (SLD) have been recently proposed by the nomenclature consensus group and endorsed by international academic liver societies. Our aim was to investigate the association between each subtype of SLD and inciden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moon, Joon Ho, Jeong, Seogsong, Jang, Heejoon, Koo, Bo Kyung, Kim, Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632413/ https://www.ncbi.nlm.nih.gov/pubmed/37954905 http://dx.doi.org/10.1016/j.eclinm.2023.102292

Ejemplares similares

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
por: Kim, Gi-Ae, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
por: Platek, Anna E., et al.
Publicado: (2023)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
por: Staufer, Katharina, et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease
por: Jeong, Seogsong, et al.
Publicado: (2022)

Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease
por: Moon, Joon Ho, et al.
Publicado: (2022)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
por: Huang, Yunqian, et al.
Publicado: (2023)

Non‐alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey
por: Moon, Joon Ho, et al.
Publicado: (2021)

Waiting for the changes after the adoption of steatotic liver disease
por: Yoon, Eileen L., et al.
Publicado: (2023)

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
por: Paklar, Natasa, et al.
Publicado: (2023)

The impact of cortisol in steatotic and non‐steatotic liver surgery
por: Cornide‐Petronio, María Eugenia, et al.
Publicado: (2017)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
por: Chan, Wah-Kheong, et al.
Publicado: (2023)

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
por: Takahashi, Yoshihisa, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs
por: Zhu, Baoqiang, et al.
Publicado: (2023)

An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
por: Kendall, Timothy J., et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
por: Eskridge, Wayne, et al.
Publicado: (2023)

Changes in m6A in Steatotic Liver Disease
por: Petri, Belinda J., et al.
Publicado: (2023)

Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers
por: Haq, Adeel, et al.
Publicado: (2023)

The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
por: Backer, Sean, et al.
Publicado: (2023)

Integrating social nutrition principles into the treatment of steatotic liver disease
por: Ivancovsky-Wajcman, Dana, et al.
Publicado: (2023)

Mitogen Activated Protein Kinases in Steatotic and Non-Steatotic Livers Submitted to Ischemia-Reperfusion
por: Jiménez-Castro, Mónica B., et al.
Publicado: (2019)

Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts
por: Da, Ben L, et al.
Publicado: (2022)

Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease
por: Semmler, Georg, et al.
Publicado: (2023)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

Hepatic Gene Expression Profiles Differentiate Steatotic and Non-steatotic Grafts in Liver Transplant Recipients
por: Šeda, Ondrej, et al.
Publicado: (2019)

The Role of Neuregulin-1 in Steatotic and Non-Steatotic Liver Transplantation from Brain-Dead Donors
por: Micó-Carnero, Marc, et al.
Publicado: (2022)

From Nonalcoholic Steatohepatits to Steatotic Liver Disease: A Long Way
por: Cotrim, Helma Pinchemel
Publicado: (2023)

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
por: Huang, Gary, et al.
Publicado: (2023)

9-PAHSA Prevents Mitochondrial Dysfunction and Increases the Viability of Steatotic Hepatocytes
por: Schultz Moreira, Adriana R., et al.
Publicado: (2020)

The Role of GLP1 in Rat Steatotic and Non-Steatotic Liver Transplantation from Cardiocirculatory Death Donors
por: Avalos-de León, Cindy G., et al.
Publicado: (2019)

Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults
por: Jeong, Seogsong, et al.
Publicado: (2022)

Association of balance impairment with risk of incident cardiovascular diseases among older adults
por: Kim, Hye Jun, et al.
Publicado: (2023)

Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
por: Lai, Jiaming, et al.
Publicado: (2023)

Embracing the principles of practice transfer to get the word out on the new metabolic dysfunction-associated steatotic liver disease nomenclature
por: Carr, Rotonya M.
Publicado: (2023)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
por: Nagai, Koki, et al.
Publicado: (2023)

Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES
por: Wu, Yanrui, et al.
Publicado: (2023)

Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
por: Al-Shargi, Amani, et al.
Publicado: (2023)

How to Preserve Steatotic Liver Grafts for Transplantation
por: Patrono, Damiano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_29f5i4rut96ertbccu72nbmbsg